Abstract Background Immune checkpoint inhibitors (ICIs) have demonstrated superior clinical efficacy in prolonging overall survival (OS) as the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC). and were recommended by the guidelines. However. it remains uncertain which ICI is the most cost-effective. https://www.roneverhart.com/Western-Digital-Ultrastar-DC-HC550-WUH721816ALE6L0-0F38460-16TB-7-2K-RPM-SATA-6Gb-s-512e-ISE-3-5in-Hard-Drive/